Nova Scotia Business Leader Joins Board of Directors HALIFAX, Oct. 17 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) a global market leader in flow-through rapid diagnostic tests, announced today that Nova Scotia business woman, Maureen Millier has been appointed to the MedMira Board of Directors. Maureen Millier is the founder, president and CEO of Talentworks Inc., a regional search firm based in Halifax, Nova Scotia. She has over 20 years experience in the local, national, and international recruitment market and has worked at various levels of the recruitment industry, from business owner to regional manager to senior vice-president of a global recruitment organization. Maureen's experience and accomplishments have been recognized in various ways including Canada's Top 40 Under 40(TM) award. "I am happy be a part of this team," said Ms. Millier. "I am looking forward to bringing my experience to the table." The Company also announced that on October 15, 2005 the Board of Directors granted 200,000 stock options to an independent member of the Board of Directors, in connection with a consulting services agreement. The options have an exercise price of $0.59 per share and are exercisable for a period of two years. The grant of options and the appointment of Ms. Millier to the Board of Directors are subject to the approval of the TSX Venture Exchange. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright